(FGFR1, 2 or 3) mutations or alterations outside of the kinase domain and regardless of prior CPI treatment receiving retifanlimab plus pemigatinib (up to 40 patients); F—CPI-experienced MSI-H EC receiving retifanlimab, INCAGN02385 (LAG-3 inhibitor), and INCAGN02390 (TIM-3 inhibitor)...
1720MO A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcomadoi:10.1016/j.annonc.2024.08.1812E. RosenbaumL-X. QinM. DicksonS. MovvaC.M. KellyJ. ChanP. Chi
1785TiP PERELI, a phase II, open label, multicenter study of pemigatinib and retifanlimab in advanced dedifferentiated liposarcomadoi:10.1016/j.annonc.2024.08.1876H. NystrmN.A. PedersenN. JunkerA. PapakonstantinouL. HanssonD. GoplenJ. Wesche...
BACKGROUND We evaluated the combination of retifanlimab, INCAGN01876, and FSRT in patients with recurrent GBM.METHODS Phase II, single-center, 2 cohort study (A: single-arm non-surgical cohort; B, two-arm neoadjuvant/surgical cohort). Cohort A patients received pre-FSRT one-time doses of...
In part 1, patients will receive intravenous (IV) INCAGN01876 at 2 dose levels (300 or 600 mg) every 2 weeks (q2w) plus IV retifanlimab 500 mg every 4 weeks (q4w). Dose escalation will follow the BOIN design algorithm until identification of a pharmacologically active dose or the ...
enhanced tumor response to PD-1 inhibitor retifanlimab.Trial design: This is a phase II multi-site single-arm clinical trial to study the combination of PD-1 inhibitor retifanlimab and the oncolytic virus Pelareorep in metastatic triple negative breast cancer who have progressed on chemotherapy....